Live biotherapeutic products: a capstone for prevention of recurrent Clostridiodes difficile infection by Kanika Sehgal, Paul Feuerstadt, Paul Feuerstadt

Get full text

The burden of CDI in the United States: a multifactorial challenge by Paul Feuerstadt, Nicolette Theriault, Glenn Tillotson

Get full text

Clinical burden of recurrent Clostridioides difficile infection in the medicare population: A real-world claims analysis by Paul Feuerstadt, Winnie W. Nelson, Christie Teigland, David N. Dahdal

Get full text

Retrospective subgroup analysis of fecal microbiota, live-jslm (REBYOTA) administered by colonoscopy under enforcement discretion for the prevention of recurrent infection by Whitfield L. Knapple, David S. Yoho, Alexander Sheh, Joan Thul, Paul Feuerstadt

Get full text

Perception of quality of life in people experiencing or having experienced a Clostridioides difficile infection: a US population survey by Lise Lurienne, Pierre-Alain Bandinelli, Thibaut Galvain, Charles-Alexis Coursel, Caterina Oneto, Paul Feuerstadt

Get full text

Safety of fecal microbiota, live-jslm (REBYOTA) in individuals with recurrent infection: data from five prospective clinical trials by Christine Lee, Thomas Louie, Lindy Bancke, Beth Guthmueller, Adam Harvey, Paul Feuerstadt, Sahil Khanna, Robert Orenstein, Erik R. Dubberke

Get full text

Efficacy and safety of prucalopride in patients with chronic idiopathic constipation stratified by age, body mass index, and renal function: a post hoc analysis of phase III and IV... by Anthony Lembo, Kyle Staller, Mena Boules, Paul Feuerstadt, William Spalding, André Gabriel, Ashraf Youssef, Yunlong Xie, Brian Terreri, Brooks D. Cash

Get full text

Efficacy and Health-Related Quality of Life Impact of Fecal Microbiota, Live-jslm: A Post Hoc Analysis of PUNCH CD3 Patients at First Recurrence of Clostridioides difficile Infecti... by Paul Feuerstadt, Jessica R. Allegretti, Erik R. Dubberke, Amy Guo, Adam Harvey, Min Yang, Viviana Garcia-Horton, Mirko Fillbrunn, Glenn Tillotson, Lindy L. Bancke, Kerry LaPlante, Kevin W. Garey, Sahil Khanna

Get full text

Integrated efficacy analysis from phase 3 studies of investigational microbiome therapeutic, SER-109, in recurrent Clostridioides difficile infection by Matthew Sims, Michael Silverman, Thomas Louie, Elaine Wang, Colleen Kraft, Mayur Ramesh, Tatiana Bogdanovich, Kelly Brady, David Lombardi, Asli Memisoglu, Ananya De, Brooke Hasson, Christine Lee, Paul Feuerstadt, Darrell Pardi, Colleen Kelly, Peter Daley, Godson Oguchi, Barbara McGovern, Lisa Von Moltke

Get full text

Integrated Safety and Efficacy Analyses of Phase 3 Trials of a Microbiome Therapeutic for Recurrent CDI by Colleen S. Kraft, Matthew Sims, Michael Silverman, Thomas J. Louie, Paul Feuerstadt, Edward S. Huang, Sahil Khanna, Charles S. Berenson, Elaine E. L. Wang, Stuart H. Cohen, Louis Korman, Christine Lee, Colleen R. Kelly, Alberto Odio, Paul P. Cook, Bret Lashner, Mayur Ramesh, Princy Kumar, Ananya De, Asli Memisoglu, David A. Lombardi, Brooke R. Hasson, Barbara H. McGovern, Lisa von Moltke, Darrell S. Pardi, on behalf of the ECOSPOR III and ECOSPOR IV investigators

Get full text

Correction to: Integrated Safety and Efficacy Analyses of Phase 3 Trials of a Microbiome Therapeutic for Recurrent CDI by Colleen S. Kraft, Matthew Sims, Michael Silverman, Thomas J. Louie, Paul Feuerstadt, Edward S. Huang, Sahil Khanna, Charles S. Berenson, Elaine E. L. Wang, Stuart H. Cohen, Louis Korman, Christine Lee, Colleen R. Kelly, Alberto Odio, Paul P. Cook, Bret Lashner, Mayur Ramesh, Princy Kumar, Ananya De, Asli Memisoglu, David A. Lombardi, Brooke R. Hasson, Barbara H. McGovern, Lisa von Moltke, Darrell S. Pardi, on behalf of the ECOSPOR III and ECOSPOR IV investigators

Get full text